Recruiting

Stem cell transplant followed by new immunotherapy for lymphoma

Plain-English translation of NCT04491370 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a treatment approach for people with B-cell lymphomas (including Hodgkin lymphoma) that have not responded well to initial therapy or have come back. The approach involves receiving a stem cell transplant followed by a new immunotherapy drug called . Researchers want to learn whether this medication is safe to give after transplant and whether it helps prevent the lymphoma from returning.

Stem cell transplants can help some patients with lymphoma, but the cancer sometimes returns. This trial is exploring whether adding this new immunotherapy after the transplant might improve long-term outcomes and keep the cancer from coming back.

Do you qualify?

You likely qualify if…

you have been diagnosed with certain B-cell lymphomas or Hodgkin lymphoma that either didn't respond to initial treatment or has returned after previous treatment
your cancer has achieved at least a partial response or stable disease after chemotherapy before entering the trial
you are well enough physically to tolerate the transplant procedure (meeting a performance status requirement)
your kidney, liver, heart, and lung function are adequate as measured by standard tests
you have had stem cells collected and stored before the trial begins
you are willing to use effective birth control during the trial if you are of reproductive age

You likely don't qualify if…

you have previously received a stem cell transplant
you have active lymphoma in your central nervous system
you currently have an uncontrolled infection
you are pregnant or breastfeeding
you have severe nerve damage (Grade 3 or higher neuropathy)

What participation looks like

First, you will receive strong chemotherapy to prepare your body for the transplant, followed by your stored stem cells being returned to you. Once you recover from the transplant and your cancer shows improvement, you will begin receiving the new immunotherapy medication as an intravenous infusion once every 3 weeks for a total of 8 doses (about 6 months). After the immunotherapy is complete, you will have follow-up visits every 4 months for about 2 years to monitor your health and check for any signs of cancer returning.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

United States

New York Medical Center, Valhalla, New York